Technical Analysis for VCNX - Vaccinex, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.72 | 2.61% | 0.12 |
VCNX closed up 2.61 percent on Thursday, December 13, 2018, on 34 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| See historical VCNX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 13 | Slingshot Bearish | Bearish Swing Setup | 0.00% |
| Dec 13 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Dec 13 | Wide Bands | Range Expansion | 0.00% |
| Dec 13 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Dec 13 | Oversold Stochastic | Weakness | 0.00% |
| Dec 12 | New 52 Week Closing Low | Bearish | 2.61% |
| Dec 12 | 180 Bearish Setup | Bearish Swing Setup | 2.61% |
| Dec 12 | Lower Bollinger Band Walk | Weakness | 2.61% |
| Dec 12 | New 52 Week Low | Weakness | 2.61% |
| Dec 12 | Stochastic Reached Oversold | Weakness | 2.61% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more VCNX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.0 |
| 52 Week Low | 4.6 |
| Average Volume | 5,070 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 6.1584 |
| 20-Day Moving Average | 5.6658 |
| 10-Day Moving Average | 5.3565 |
| Average True Range | 0.5529 |
| ADX | 24.72 |
| +DI | 14.8006 |
| -DI | 27.1471 |
| Chandelier Exit (Long, 3 ATRs ) | 5.2313 |
| Chandelier Exit (Short, 3 ATRs ) | 6.2587 |
| Upper Bollinger Band | 6.653 |
| Lower Bollinger Band | 4.6786 |
| Percent B (%b) | 0.02 |
| BandWidth | 34.847683 |
| MACD Line | -0.388 |
| MACD Signal Line | -0.3242 |
| MACD Histogram | -0.0638 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.95 | ||||
| Resistance 3 (R3) | 6.06 | 5.77 | 5.75 | ||
| Resistance 2 (R2) | 5.77 | 5.45 | 5.71 | 5.68 | |
| Resistance 1 (R1) | 5.24 | 5.26 | 5.51 | 5.13 | 5.61 |
| Pivot Point | 4.95 | 4.95 | 5.08 | 4.89 | 4.95 |
| Support 1 (S1) | 4.42 | 4.63 | 4.69 | 4.31 | 3.83 |
| Support 2 (S2) | 4.13 | 4.44 | 4.07 | 3.76 | |
| Support 3 (S3) | 3.60 | 4.13 | 3.70 | ||
| Support 4 (S4) | 3.49 |
